Dr. Dave Moskowitz, CEO and Chief Medical Officer of GenoMed, Inc based in the United States participates in Risk Roundup to discuss the Risks and Rewards of Genomic Medicine. Genomic Medicine – Risks & Rewards The promise of Genomic Medicine is here! It seems across nations, thousands of individuals are already being diagnosed, treated, or having their treatment changed, based on the information gathered from their individual genome. This is possible due to the advances in technology and speed of DNA sequencing and analysis, which now permits near real-time disease diagnosis, helping it to move it into the clinical workflow and decision-making process. The increasing availability of thousands of genomic tests for disease diagnosis, several targeted drug therapies, and the use of pharmacogenomic data for drug and dosage selection implies that genomics is on its way to getting integrated into the healthcare delivery model across many nations. This brings us the real potential to change healthcare from being reactive care to truly preventive care that is personalized. It is important to evaluate this further: The current state of diagnostic genomicsState of diagnosis of complex diseasesAdvantages of genome-scale technologiesGenomic medicineThe current state of the healthcare system in enabling genomic medicine Conclusion – Genomic Medicine – Risks & Rewards Privacy and Security are critical if Genomic Medicine is to successfully integrate into healthcare. Time is now to discuss Genomic Medicine Risks and Rewards! For more please watch the Risk Roundup Webcast or hear the Risk Roundup Podcast About the Guest Dr. Dave Moskowitz MD is a Nephrologist and Founder, CEO, and Chief Medical Officer of GenoMed Inc (http://genomed.com ). Genomed, a Next Generation DM(tm) company (DM = Disease Management), is a patient-friendly company that does business over the Internet. They use cutting-edge, genomics-based medicine to lower healthcare costs and consider themselves pioneers in preventive molecular medicine. About Risk Group Risk Group is a leading strategic security risk research and reporting organization. Copyright Risk Group LLC. All Rights Reserved Reference Episodes Future of Work – Battle between Human Work Force and Machine Work ForceTechnology Trends and Future of HumanityTechnology Trends and HumanificationDual Use Technology Dilemma and National Security RisksElectronic Warfare PreparednessFuture of TechnologyDigital Future – Complex Challenges of ChangeElectronic Warfare-An Existential RiskElectromagnetic WarfareWhat Role Gene Environment Plays In Gene Expression And Human Health SecurityFourth Industrial Revolution and SecurityMachine Learning Bias – An Existential RiskCompetitive Intelligence and Risk ManagementStrategic IntelligenceDisruptive Innovation and Security RisksDiagnostic Genomics and Security RisksNanoSatellites & Democratization of SpaceHealthcare in TurmoilSpace MiningSpace SecurityImpact InvestingBioEconomy – Promise and Perils of Synthetic BiologySocietal Impact of RoboticsComplex Security Risks of Mediterranean RegionAre Education Institutions Prepared for Digital DisruptionDigital Disruption in MarketingThe Middle East Geopolitical Puzzle and Risks to Global SecurityImpact of Cyber-Security Risks Global BusinessThe Digital Global Age – Contested CommonsStrategizing Digital TransformationStrategizing Cyber-SecurityEnergy Warfare The post Risks and Rewards of Genomic Medicine appeared first on Risk Group.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related